Alevin is delighted to be a finalist for Start-up of the Year at the Cambridge Independent Science and Technology Awards 2023. The awards, to be held in Cambridge on the 18th May 2023, showcase the breadth of innovative technologies across the Cambridge region.
Alevin’s place on the shortlist highlights the rich potential in the company’s pipeline, which is focussed on small molecule RGD integrin inhibitors for treatment of diseases with high unmet clinical need, such as fibrosis, kidney disease and cancer. Alevin’s lead asset, ALV296, is a inhaled drug for the treatment of idiopathic pulmonary fibrosis.
Sunil Shah, Chair of Alevin Therapeutics said
“The nomination for Start-up of the Year reflects the exciting science in Alevin. We are committed to progressing our compounds, and hope to be a clinical stage biotech by 2024.”